| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA920: Tofacitinib for treating active ankylosing spondylitis |
|
Medicine details |
|
| Medicine name | tofacitinib (Xeljanz®) |
| Formulation | 5 mg, 10 mg film coated tablets |
| Reference number | 4250 |
| Indication | Treatment of ankylosing spondylitis in adults who have responded inadequately to conventional therapy |
| Company | Pfizer Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/12/2021 |
| NICE guidance | TA920: Tofacitinib for treating active ankylosing spondylitis |